Beatriz Cuevas

912 total citations
16 papers, 163 citations indexed

About

Beatriz Cuevas is a scholar working on Hematology, Genetics and Infectious Diseases. According to data from OpenAlex, Beatriz Cuevas has authored 16 papers receiving a total of 163 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 8 papers in Genetics and 3 papers in Infectious Diseases. Recurrent topics in Beatriz Cuevas's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers), Acute Myeloid Leukemia Research (6 papers) and Multiple Myeloma Research and Treatments (4 papers). Beatriz Cuevas is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers), Acute Myeloid Leukemia Research (6 papers) and Multiple Myeloma Research and Treatments (4 papers). Beatriz Cuevas collaborates with scholars based in Spain, Mexico and Chile. Beatriz Cuevas's co-authors include María Teresa Gómez‐Casares, Alberto Álvarez‐Larrán, Francisca Ferrer‐Marín, Valentín García‐Gutiérrez, Juan Carlos Hernández‐Boluda, Roberto Zenteno‐Cuevas, Manuel Pérez‐Encinas, Abelardo Bárez, Ana Kerguelen and María Antonia Durán and has published in prestigious journals such as Blood, British Journal of Haematology and Thrombosis and Haemostasis.

In The Last Decade

Beatriz Cuevas

13 papers receiving 163 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Beatriz Cuevas Spain 7 87 83 59 43 34 16 163
Monica Maccaferri Italy 7 53 0.6× 76 0.9× 16 0.3× 31 0.7× 20 0.6× 17 160
Shunsuke Hatta Japan 9 46 0.5× 39 0.5× 80 1.4× 16 0.4× 16 0.5× 24 185
Nadine Müller Germany 5 43 0.5× 48 0.6× 12 0.2× 58 1.3× 104 3.1× 9 241
Tamara Belotti Italy 10 50 0.6× 18 0.2× 19 0.3× 26 0.6× 37 1.1× 16 163
Tanja Gromke Germany 7 212 2.4× 44 0.5× 27 0.5× 31 0.7× 170 5.0× 17 374
Daniel Suez United States 10 121 1.4× 86 1.0× 20 0.3× 29 0.7× 36 1.1× 21 268
Ana Kerguelen Spain 9 177 2.0× 224 2.7× 126 2.1× 104 2.4× 15 0.4× 11 275
Clémence Mediavilla France 8 88 1.0× 31 0.4× 26 0.4× 9 0.2× 27 0.8× 18 137
Johanna Elin Gehin Norway 8 37 0.4× 29 0.3× 16 0.3× 98 2.3× 25 0.7× 29 197
Jane Kempenich United States 7 106 1.2× 14 0.2× 36 0.6× 14 0.3× 25 0.7× 15 304

Countries citing papers authored by Beatriz Cuevas

Since Specialization
Citations

This map shows the geographic impact of Beatriz Cuevas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beatriz Cuevas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beatriz Cuevas more than expected).

Fields of papers citing papers by Beatriz Cuevas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beatriz Cuevas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beatriz Cuevas. The network helps show where Beatriz Cuevas may publish in the future.

Co-authorship network of co-authors of Beatriz Cuevas

This figure shows the co-authorship network connecting the top 25 collaborators of Beatriz Cuevas. A scholar is included among the top collaborators of Beatriz Cuevas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beatriz Cuevas. Beatriz Cuevas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Stuckey, Ruth, Marta Sobas, Alberto Álvarez‐Larrán, et al.. (2024). DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study. Thrombosis and Haemostasis. 124(7). 669–675. 3 indexed citations
2.
Labrador, Jorge, et al.. (2023). Bortezomib Pharmacogenetic Biomarkers for the Treatment of Multiple Myeloma: Review and Future Perspectives. Journal of Personalized Medicine. 13(4). 695–695. 6 indexed citations
3.
Hernández‐Boluda, Juan Carlos, Alberto Álvarez‐Larrán, José María Raya, et al.. (2022). Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. Cancers. 14(9). 2331–2331. 3 indexed citations
4.
Labrador, Jorge, Pablo Zubiaur, Beatriz Cuevas, et al.. (2022). Pharmacogenetic Study of Ibrutinib Toxicity in Chronic Lymphocytic Leukemia Patients. Blood. 140(Supplement 1). 12405–12406. 2 indexed citations
5.
Saiz‐Rodríguez, Miriam, Jorge Labrador, Beatriz Cuevas, et al.. (2021). Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis. Cancers. 13(22). 5677–5677. 9 indexed citations
6.
González‐López, Tomás José, Sergio Matarraz, María Fernanda López Fernández, et al.. (2021). Contribution of Next Generation Flow (NGF) Cytometry in Primary Immune Thrombocytopenia (ITP): Utility for the Differential Diagnosis with Myelodysplastic Syndromes. Blood. 138(Supplement 1). 4219–4219.
7.
Álvarez‐Larrán, Alberto, Arturo Pereira, Marta Magaz, et al.. (2020). Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis. Annals of Hematology. 99(4). 791–798. 17 indexed citations
8.
Saiz‐Rodríguez, Miriam, Beatriz Cuevas, David Martínez‐Cuadrón, et al.. (2020). Comparison of Azacitidine and Decitabine for the Treatment of Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Blood. 136(Supplement 1). 35–36. 1 indexed citations
9.
Cuevas, Beatriz, et al.. (2019). Cost of incorrect application of antithrombotic prophylaxis prior to invasive procedures. BMC Health Services Research. 19(1). 802–802. 2 indexed citations
10.
Pereira, Arturo, Carlos Besses Raebel, Juan Carlos Hernández‐Boluda, et al.. (2018). Excess Mortality in Polycythemia Vera and Essential Thrombocythemia. Blood. 132(Supplement 1). 3042–3042. 2 indexed citations
11.
Vallejo, Carlos, Pau Montesinos, Marta Polo, et al.. (2015). Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis. Annals of Hematology. 94(6). 947–954. 25 indexed citations
12.
Vázquez, Lourdes, Fernando Ramos, Beatriz Cuevas, et al.. (2015). Incidence of haematological neoplasms in Castilla y León, Spain. Medicina Clínica (English Edition). 144(11). 491–500.
13.
Álvarez‐Larrán, Alberto, Ana Kerguelen, Juan Carlos Hernández‐Boluda, et al.. (2015). Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. British Journal of Haematology. 172(5). 786–793. 57 indexed citations
14.
Vázquez, Lourdes, Fernando Ramos, Beatriz Cuevas, et al.. (2014). Estudio de incidencia de las neoplasias hematopoyéticas en Castilla y León. Medicina Clínica. 144(11). 491–500.
15.
Zenteno‐Cuevas, Roberto, et al.. (2009). Mutations in rpoB and katG genes in Mycobacterium isolates from the Southeast of Mexico. Memórias do Instituto Oswaldo Cruz. 104(3). 468–472. 29 indexed citations
16.
Fajardo-Dolci, Germán, et al.. (2006). Primary tuberculosis of the tonsil. International Journal of Pediatric Otorhinolaryngology Extra. 1(2). 150–153. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026